

Louisiana Fee-for-Service Medicaid Pyrimethamine (Daraprim®)

Pyrimethamine (Daraprim®) requires clinical authorization. The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request authorization for pyrimethamine (Daraprim®).

Initial and reauthorization requests for pyrimethamine will be considered for approval if all of the following criteria are met:

1. Recipient has a diagnosis of toxoplasmosis; **OR**
2. Recipient has a diagnosis of human immunodeficiency virus infection; **AND**
3. Recipient is being treated concomitantly with **BOTH** of the following medications:
 - a. A sulfonamide (or clindamycin if sulfonamide is contraindicated or not tolerated); **AND**
 - b. Leucovorin calcium (folinic acid); **AND**
4. By submitting the authorization request, the prescriber attests to the following:
 - a. The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
 - b. All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
 - c. The recipient has no inappropriate concomitant drug therapies or disease states.

Duration of authorization for acute infection: 2 months

Duration of authorization for chronic maintenance treatment or infection prophylaxis: 12 months

References:

Centers for Disease Control and Prevention (CDC): Parasites - Toxoplasmosis (Toxoplasma infection). (2017, April 10). Retrieved from https://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html/

Daraprim (pyrimethamine) [package insert]. New York, NY: Viera Pharmaceuticals; August 2017. Retrieved from <https://www.daraprimdirect.com/Content/downloads/DAR2017062-Portrait-201708-PI.PDF>

Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Retrieved from http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf